Modus Therapeutics Holding AB (OSTO:MODTX) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Debt-to-Equity?

Modus Therapeutics Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Modus Therapeutics Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Modus Therapeutics Holding AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr14.58 Mil. Modus Therapeutics Holding AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Modus Therapeutics Holding AB's Debt-to-Equity or its related term are showing as below:

OSTO:MODTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.45 Med: -1.13 Max: 1.7
Current: 1.27

During the past 5 years, the highest Debt-to-Equity Ratio of Modus Therapeutics Holding AB was 1.70. The lowest was -4.45. And the median was -1.13.

OSTO:MODTX's Debt-to-Equity is ranked worse than
89.91% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:MODTX: 1.27

Modus Therapeutics Holding AB Debt-to-Equity Historical Data

The historical data trend for Modus Therapeutics Holding AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB Debt-to-Equity Chart

Modus Therapeutics Holding AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.95

-4.45

Modus Therapeutics Holding AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												-1.62	-1.24	-1.13	-	-

Competitive Comparison of Modus Therapeutics Holding AB's Debt-to-Equity

For the Biotechnology subindustry, Modus Therapeutics Holding AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Modus Therapeutics Holding AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Modus Therapeutics Holding AB's Debt-to-Equity falls into.

Modus Therapeutics Holding AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Modus Therapeutics Holding AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	17.682
	=	0.00

Modus Therapeutics Holding AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	14.577
	=	0.00

Modus Therapeutics Holding AB (OSTO:MODTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Modus Therapeutics Holding AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Modus Therapeutics Holding AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Modus Therapeutics Holding AB (OSTO:MODTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (OSTO:MODTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Olof Palmes gata 29 IV, Stockholm, SWE, 11122

Website

https://www.modustx.com

Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis and septic shock through the patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB (OSTO:MODTX) Headlines

No Headlines